HK1147946A1 - Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season - Google Patents

Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season

Info

Publication number
HK1147946A1
HK1147946A1 HK11102130.4A HK11102130A HK1147946A1 HK 1147946 A1 HK1147946 A1 HK 1147946A1 HK 11102130 A HK11102130 A HK 11102130A HK 1147946 A1 HK1147946 A1 HK 1147946A1
Authority
HK
Hong Kong
Prior art keywords
allergen
mucosomal
specific immunotherapy
pollen season
initial dosing
Prior art date
Application number
HK11102130.4A
Other languages
English (en)
Inventor
Eike Gunther Wuestenberg
Eckhard-Carl Albrecht Puchert
Original Assignee
Alk Abello As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39809974&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1147946(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alk Abello As filed Critical Alk Abello As
Publication of HK1147946A1 publication Critical patent/HK1147946A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK11102130.4A 2008-04-11 2011-03-03 Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season HK1147946A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4440108P 2008-04-11 2008-04-11
DKPA200800533 2008-04-11
PCT/EP2009/054186 WO2009124954A1 (en) 2008-04-11 2009-04-08 Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season

Publications (1)

Publication Number Publication Date
HK1147946A1 true HK1147946A1 (en) 2011-08-26

Family

ID=39809974

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11102130.4A HK1147946A1 (en) 2008-04-11 2011-03-03 Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season

Country Status (13)

Country Link
US (2) US9248097B2 (xx)
EP (1) EP2265285B1 (xx)
JP (2) JP5618981B2 (xx)
CN (1) CN102014954A (xx)
AU (1) AU2009235490B2 (xx)
BR (1) BRPI0911433A2 (xx)
CA (1) CA2720455A1 (xx)
DE (1) DE202008006598U1 (xx)
EA (1) EA019202B1 (xx)
ES (1) ES2406391T3 (xx)
HK (1) HK1147946A1 (xx)
MX (1) MX2010011012A (xx)
WO (1) WO2009124954A1 (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003280324A1 (en) * 2002-11-26 2004-06-18 Alk-Abello A/S Pharmaceutical allergen product
DE202008006598U1 (de) * 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
WO2012049310A1 (en) 2010-10-15 2012-04-19 Alk-Abelló A/S Suppression of a hypersensitivity immune response with unrelated antigen derived from allergen source material
WO2012049312A1 (en) * 2010-10-15 2012-04-19 Alk-Abelló A/S Suppression of a type 1 hypersensitivity immune response with an unrelated antigen
WO2012148549A1 (en) 2011-02-25 2012-11-01 Benaroya Research Institute Detection of an immune response
JP2012240975A (ja) * 2011-05-20 2012-12-10 Nitto Denko Corp 医薬組成物及びゼリー状製剤
JP2012240978A (ja) * 2011-05-20 2012-12-10 Nitto Denko Corp 医薬組成物及びゼリー状製剤
CA3208225A1 (en) 2012-01-16 2013-07-25 Elizabeth Mckenna Compositions and methods for the treatment of hepatitic diseases and disorders
EP4324479A3 (en) 2012-08-21 2024-04-24 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
WO2014047588A1 (en) 2012-09-21 2014-03-27 Elizabeth Mckenna Naturally occurring cpg oligonucleotide compositions and therapeutic applications thereof
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
ES2973858T3 (es) 2014-02-28 2024-06-24 Regeneron Pharma Métodos para tratar infecciones cutáneas mediante la administración de un antagonista de IL-4R
JP6861630B2 (ja) 2014-11-14 2021-04-21 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法
MA46098A (fr) 2016-09-01 2019-07-10 Regeneron Pharma Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r
TW202332696A (zh) 2016-12-01 2023-08-16 美商再生元醫藥公司 治療發炎症狀的方法
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
MA46269B1 (fr) 2017-08-18 2024-05-31 Regeneron Pharma Méthodes de traitement d'une dermatite atopique sévère par administration d'un inhibiteur des il-4r
CN111526920A (zh) 2017-10-30 2020-08-11 赛诺菲生物技术公司 通过施用il-4r拮抗剂来治疗或预防哮喘的方法
BR112020020387A2 (pt) 2018-05-13 2021-01-19 Regeneron Pharmaceuticals, Inc. Métodos para o tratamento de dermatite atópica por administração de um inibidor de il-4r
AU2020240132A1 (en) 2019-03-21 2021-09-16 Regeneron Pharmaceuticals, Inc. Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
CN114173819A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK137992D0 (da) 1992-11-13 1992-11-13 Alk Lab As Fremgangsmaade til paavisning af et immunologisk aktivt stof i en proeve under anvendelse af et maerkningsstof
JPH0959179A (ja) * 1995-08-28 1997-03-04 Japan Tobacco Inc スギ花粉症予防性を有する口腔衛生剤
IL138339A0 (en) 1998-03-16 2001-10-31 Alk Abello As Mutant recombinant allergens
FR2778244B1 (fr) 1998-04-30 2000-07-13 Univ Joseph Fourier Procede d'excitation d'une cavite optique pour la detection de gaz a l'etat de traces
NZ525820A (en) 2000-11-16 2005-01-28 Alk Abello As Mutant allergens
WO2003096869A2 (en) 2002-05-16 2003-11-27 Alk Abelló A/S Recombinant bet. v. 1. allergen mutants, methods and process thereof
AU2003280324A1 (en) 2002-11-26 2004-06-18 Alk-Abello A/S Pharmaceutical allergen product
WO2005077410A1 (en) 2004-02-06 2005-08-25 Greer Laboratories, Inc. Methods and compositions for dosing of allergens
CA2556557A1 (en) * 2004-02-26 2005-09-09 Alk Abello A/S Method of evaluating the therapeutic potential of a vaccine for mucosal administration
US20060115499A1 (en) 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
PT1812059E (pt) 2004-11-10 2010-07-26 Alk Abelle As MéTODO DE TRATAMENTO PREVENTIVO DA ALERGIA POR ADMINISTRAÆO POR VIA MUCOSAL DE UMA VACINA PARA A ALERGIA
JP5628473B2 (ja) 2004-11-10 2014-11-19 アルク−アベッロ エイ／エスＡｌｋ−Ａｂｅｌｌｏ Ａ／Ｓ アレルギーワクチンの粘膜投与によるアレルギーの予防治療方法
CN101098711A (zh) * 2005-01-07 2008-01-02 阿尔克-阿贝洛有限公司 通过口粘膜施用***反应疫苗预防性治疗***反应的方法
US20060210590A1 (en) * 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
KR20080059289A (ko) 2005-10-04 2008-06-26 알크-아벨로 에이/에스 고체 백신 제형
EP1814516B1 (en) 2005-11-04 2012-12-26 Alk-Abelló A/S Use of a liquid allergy vaccine formulation for oromucosal administration
DE202007004567U1 (de) 2007-03-28 2007-10-11 Alk-Abelló A/S Verwendung einer adjuvierten Allergievakzinformulierung zur parenteralen Verabreichung
CN101674845A (zh) * 2007-03-28 2010-03-17 阿尔克-阿贝洛有限公司 用于胃肠外给药的佐剂疫苗制剂的用途
DE202008006598U1 (de) * 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung

Also Published As

Publication number Publication date
EA019202B1 (ru) 2014-01-30
WO2009124954A1 (en) 2009-10-15
EP2265285A1 (en) 2010-12-29
BRPI0911433A2 (pt) 2016-07-26
CN102014954A (zh) 2011-04-13
US20110142934A1 (en) 2011-06-16
DE202008006598U1 (de) 2008-10-02
EA201071182A1 (ru) 2011-06-30
CA2720455A1 (en) 2009-10-15
JP5618981B2 (ja) 2014-11-05
EP2265285B1 (en) 2013-03-20
US20140127298A1 (en) 2014-05-08
AU2009235490A1 (en) 2009-10-15
JP2011516521A (ja) 2011-05-26
AU2009235490B2 (en) 2013-10-24
JP2015013891A (ja) 2015-01-22
ES2406391T3 (es) 2013-06-06
MX2010011012A (es) 2010-11-12
US9248097B2 (en) 2016-02-02

Similar Documents

Publication Publication Date Title
HK1147946A1 (en) Mucosomal allergen-specific immunotherapy with initial dosing after start of pollen season
MX2009010092A (es) Anticuerpos anti ige apoptoticos.
MX2012001194A (es) Peptidos tau antigenicos y usos de los mismos.
NZ597763A (en) Methods for treatment of pain
WO2011069141A3 (en) Interferon therapies in combination with blockade of stat3 activation
WO2009154840A3 (en) Compositions and methods using stem cells in cutaneous wound healing
TN2015000027A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
EA201291034A1 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ B-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MX2012010161A (es) Metodo para tratar el mal de parkinson.
LT2254869T (lt) Nauji 1-benzil-3-hidroksimetilindazolo dariniai ir jų panaudojimas gydyme ligų, susijusių su cx3cr1 ir p40 raiška
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
WO2009142772A3 (en) Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
IL210545A (en) Transplantation devices for use of octreotide transport and use of octreotide to create drugs
WO2011112867A8 (en) The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
AR082312A1 (es) Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos
NZ602380A (en) Peptides for vaccine against birch allergy
MX2013003160A (es) Composiciones farmaceuticas solidas antidiabeticas.
EA200970816A1 (ru) Новая лекарственная форма
CO6541630A2 (es) Combinación teobromina con un descongestivo y su uso para el tratamiento de la tos
MX2013012967A (es) Composicion de miel con l-alanil-l-glutamina.
WO2009109855A3 (en) Immunotherapy for unresectable pancreatic cancer
TW200610532A (en) Anti-stress composition
EP1974746A3 (en) Use of an adjuvanted allergy vaccine formulation for parenteral administration

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200405